{"id":46127,"date":"2022-07-13T15:01:54","date_gmt":"2022-07-13T13:01:54","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/health-canada-clears-cuteras-aviclear\/"},"modified":"2022-07-13T15:01:54","modified_gmt":"2022-07-13T13:01:54","slug":"health-canada-clears-cuteras-aviclear","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/health-canada-clears-cuteras-aviclear\/","title":{"rendered":"Health Canada Clears Cutera\u2019s AviClear\u2122"},"content":{"rendered":"
\n

\nThe First and Only Device in North America Cleared for the Treatment of Mild, Moderate and Severe Acne<\/i><\/b>\n<\/p>\n

\nAviClear has been Proven Safe and Effective Through an Extensive Clinical Trial<\/i>\n<\/p>\n

\nProvides Long-term Resolution of Acne Across All Skin Types<\/i>\n<\/p>\n

TORONTO–(BUSINESS WIRE)–Cutera, Inc. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, today announced that AviClear, the first and only energy device approved in the United States for the treatment of mild, moderate, and severe acne, has secured clearance from Health Canada for the treatment of mild, moderate, and severe acne and acne scars. This Health Canada announcement comes on the heels of the U.S. Food and Drug Administration\u2019s 510(k) clearance of AviClear, in March 2022.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nAviClear is a laser treatment that offers a safe, effective, prescription-free solution for acne. In addition to reducing existing acne, clinical trials show that future breakout episodes are shorter, less intense, and more infrequent following three 30-minute treatment sessions. Further, acne clearance results continue to improve over time, demonstrating the long-term efficacy of this novel treatment. Importantly, no pain mitigation was utilized or required by any clinical study participant.1<\/sup>\n<\/p>\n

\nAcne vulgaris is a nearly universal skin disease, with approximately 50 million North American teens and young adults seeking treatment each year.2<\/sup> AviClear\u2019s 1726nm wavelength treats acne at the source by selectively targeting the sebocytes and suppressing sebum production. Overproduction of sebum by the sebaceous glands is one of the leading causes of acne.3<\/sup>\n<\/p>\n

\n\u201cAcne affects so many people \u2013 from teens to women in menopause, and everyone in between,\u201d said Jerry K. L. Tan, MD, FRCPC. \u201cI am thrilled that AviClear can offer patients a safe, effective, and drug-free treatment option that will help them face the world without the worry, frustration or self-consciousness that often accompanies acne.\u201d\n<\/p>\n

\n\u201cWe are ecstatic with AviClear\u2019s expansion into the Canadian market as an innovative tool for dermatologists and as a treatment that inspires hope for acne patients,\u201d said David Mowry, CEO of Cutera. “Developed with extensive physician and patient input, AviClear is helping to redefine and optimize modern acne care.\u201d\n<\/p>\n

\nCanadian doctors and consumers are encouraged to visit www.AviClear.com<\/a> and sign up for updates on product availability and local treatment providers. Cutera is planning for measured expansion of AviClear to Canadian providers in their limited commercial release over the course of 2022.\n<\/p>\n

\nAbout Cutera, Inc.<\/b>\n<\/p>\n

\nBrisbane, California-based Cutera is a leading provider of aesthetic and dermatology solutions for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that harness the power of science and nature to enable medical practitioners to offer safe and effective treatments to their patients. For more information, call +1 415-657-5500 or 1-888-4CUTERA or visit www.cutera.com.<\/a>\n<\/p>\n

\nReferences\n<\/p>\n

    \n
  1. \nData on file, FDA clearance study. Cutera, Inc.\n<\/li>\n
  2. \nhttps:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/479093<\/a>\n<\/li>\n
  3. \nO\u2019Neill AM, Gallo RL. Host-microbiome interactions and recent progress into understanding the biology of acne vulgaris. Microbiome 2018;6: 177.\n<\/li>\n<\/ol>\n

    \n\u00a0\n<\/p>\n

    Contacts<\/b> <\/p>\n

    \nMedia:
    \n
    <\/b>    cutera@talkshopmedia.com<\/a>\n<\/p>\n

    \nMarketing Communications:<\/b>
    Erica Dement \u2013     edement@cutera.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

    The First and Only Device in North America Cleared for the Treatment of Mild, Moderate and Severe Acne AviClear has been Proven Safe and Effective Through an Extensive Clinical Trial Provides Long-term Resolution of Acne Across All Skin Types TORONTO–(BUSINESS WIRE)–Cutera, Inc. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, today announced that … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-46127","format-standard","category-industry"],"yoast_head":"\nHealth Canada Clears Cutera\u2019s AviClear\u2122 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/health-canada-clears-cuteras-aviclear\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Health Canada Clears Cutera\u2019s AviClear\u2122 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"The First and Only Device in North America Cleared for the Treatment of Mild, Moderate and Severe Acne AviClear has been Proven Safe and Effective Through an Extensive Clinical Trial Provides Long-term Resolution of Acne Across All Skin Types TORONTO–(BUSINESS WIRE)–Cutera, Inc. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, today announced that ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/health-canada-clears-cuteras-aviclear\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-13T13:01:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220713005256\/en\/1512034\/21\/AviClear_Console_with_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/health-canada-clears-cuteras-aviclear\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/health-canada-clears-cuteras-aviclear\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Health Canada Clears Cutera\u2019s AviClear\u2122\",\"datePublished\":\"2022-07-13T13:01:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/health-canada-clears-cuteras-aviclear\\\/\"},\"wordCount\":502,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/health-canada-clears-cuteras-aviclear\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220713005256\\\/en\\\/1512034\\\/21\\\/AviClear_Console_with_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/health-canada-clears-cuteras-aviclear\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/health-canada-clears-cuteras-aviclear\\\/\",\"name\":\"Health Canada Clears Cutera\u2019s AviClear\u2122 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/health-canada-clears-cuteras-aviclear\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/health-canada-clears-cuteras-aviclear\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220713005256\\\/en\\\/1512034\\\/21\\\/AviClear_Console_with_Logo.jpg\",\"datePublished\":\"2022-07-13T13:01:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/health-canada-clears-cuteras-aviclear\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/health-canada-clears-cuteras-aviclear\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/health-canada-clears-cuteras-aviclear\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220713005256\\\/en\\\/1512034\\\/21\\\/AviClear_Console_with_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220713005256\\\/en\\\/1512034\\\/21\\\/AviClear_Console_with_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/health-canada-clears-cuteras-aviclear\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Health Canada Clears Cutera\u2019s AviClear\u2122\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Health Canada Clears Cutera\u2019s AviClear\u2122 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/health-canada-clears-cuteras-aviclear\/","og_locale":"en_US","og_type":"article","og_title":"Health Canada Clears Cutera\u2019s AviClear\u2122 - Pharma Trend","og_description":"The First and Only Device in North America Cleared for the Treatment of Mild, Moderate and Severe Acne AviClear has been Proven Safe and Effective Through an Extensive Clinical Trial Provides Long-term Resolution of Acne Across All Skin Types TORONTO–(BUSINESS WIRE)–Cutera, Inc. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, today announced that ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/health-canada-clears-cuteras-aviclear\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-13T13:01:54+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220713005256\/en\/1512034\/21\/AviClear_Console_with_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/health-canada-clears-cuteras-aviclear\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/health-canada-clears-cuteras-aviclear\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Health Canada Clears Cutera\u2019s AviClear\u2122","datePublished":"2022-07-13T13:01:54+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/health-canada-clears-cuteras-aviclear\/"},"wordCount":502,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/health-canada-clears-cuteras-aviclear\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220713005256\/en\/1512034\/21\/AviClear_Console_with_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/health-canada-clears-cuteras-aviclear\/","url":"https:\/\/pharma-trend.com\/en\/health-canada-clears-cuteras-aviclear\/","name":"Health Canada Clears Cutera\u2019s AviClear\u2122 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/health-canada-clears-cuteras-aviclear\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/health-canada-clears-cuteras-aviclear\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220713005256\/en\/1512034\/21\/AviClear_Console_with_Logo.jpg","datePublished":"2022-07-13T13:01:54+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/health-canada-clears-cuteras-aviclear\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/health-canada-clears-cuteras-aviclear\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/health-canada-clears-cuteras-aviclear\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220713005256\/en\/1512034\/21\/AviClear_Console_with_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220713005256\/en\/1512034\/21\/AviClear_Console_with_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/health-canada-clears-cuteras-aviclear\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Health Canada Clears Cutera\u2019s AviClear\u2122"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46127","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46127"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46127\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46127"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46127"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46127"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}